Crystal Pharmaceutical (suzhou) Co., Ltd.

Crystal Pharmatech Co., Ltd.

Crystal Pharmaceutical Co., Ltd.

Qiyue Liu

Yanfeng Zhang

Minhua Chen

Xiaoyu Zhang

Chaohui Yang

Kaiqiang Yan

Nan Xia

Jiaoyang Li

The present disclosure relates to crystalline forms of Baricitinib and processes for preparation thereof. The present disclosure also relates to pharmaceutical composition containing these crystalline forms and use of these crystalline forms for preparing JAK inhibitor drugs and preparing drugs treating rheumatoid arthritis. The crystalline forms of the present disclosure have one or more improved properties compared with crystalline forms of the prior art and have significant values for future drug optimization and development. 

Crystal form of Baricitinib and preparation method thereof

The present disclosure relates to novel crystalline forms of an androgen receptor antagonist drug (ODM-201 represented by formula (I)), preparation method thereof and use thereof. The crystalline form B or the crystalline form C of ODM-201 provided by the present disclosure has low hygroscopicity, good stability, high solubility, excellent flowability, optimal particle size with uniform distribution, which provides a new choice for the preparation of drugs containing ODM-201 and is of great value for drug development. 

Crystal forms of an androgen receptor antagonist, preparation method and use thereof

The present disclosure relates to novel co-crystals of a CDK inhibitor and an MEK inhibitor and the preparation methods thereof. Specifically, the present disclosure provides hydrates or anhydrates which are named as Form I, Form II and Form III. The novel co-crystals provided in the present disclosure have good stability, low hygroscopicity and high solubility, and have an important value for further optimization and development of the drug. 

Co-crystal of a CDK inhibitor and an MEK inhibitor and process of preparation thereof

Growing community of inventors

Jiangsu, China

Qiyue Liu